At the forefront of biomedical innovation, Progenra is pioneering the development of precision medicines to treat mitochondrial diseases—devastating disorders with limited therapeutic options. By harnessing cutting-edge science in mitochondrial biology, bioenergetics, and protein quality control, we are advancing novel small molecules that target the root causes of mitochondrial dysfunction. Our platform integrates genetic insights, disease models, sensitive biomarker assays and state-of-the-art drug discovery technologies to deliver first-in-class and best-in-class therapeutics. We aim to transform the lives of patients by restoring mitochondrial health and unlocking new possibilities for treating rare and common diseases driven by cellular energy failure.